BMY|Bristol-Myers Squibb Co|Preço:61.990|Var. %:2.42

Mais detalhes de Bristol-Myers Squibb Co Empresa

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Informações de Bristol-Myers Squibb Co



Código da empresaBMY

Nome da EmpresaBristol-Myers Squibb Co

Data de listagemMar 17, 1980

CEOBoerner (Christopher S)

Número de funcionários34100

Tipo de títulosOrdinary Share

Fim do ano fiscalMar 17

EndereçoRoute 206 And Province Line Road

CidadePRINCETON

Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE

PaísUnited States of America

Código postal08543

Telefone16092524621

Sitehttps://www.bms.com

Código da empresaBMY

Data de listagemMar 17, 1980

CEOBoerner (Christopher S)

Executivos da empresa Bristol-Myers Squibb Co



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer

63.90K

+1182.00%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

19.77K

+3068.00%

Dr. Julia A. Haller, M.D.

Independent Director

13.62K

--

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

12.44K

+5789.00%

Ms. Cari Gallman

Executive Vice President, General Counsel and Chief Policy Officer

11.07K

+2226.00%

Ms. Phyllis R. Yale

Independent Director

--

Mr. David V. Elkins

Executive Vice President, Chief Financial Officer, Member of the Leadership Team

--

Ms. Paula A. Price

Independent Director

--

Mr. Derica W. Rice

Independent Director

--

Dr. Manuel Hidalgo Medina, M.D., Ph.D.

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer

63.90K

+1182.00%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

19.77K

+3068.00%

Dr. Julia A. Haller, M.D.

Independent Director

13.62K

--

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

12.44K

+5789.00%

Ms. Cari Gallman

Executive Vice President, General Counsel and Chief Policy Officer

11.07K

+2226.00%

Ms. Phyllis R. Yale

Independent Director

--

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por EmpresaUSD

Nome

Receita

Proporção

Eliquis

3.75B

30.65%

Opdivo

2.60B

21.26%

Orencia

964.00M

7.89%

Yervoy

739.00M

6.05%

Other

691.00M

5.65%

Outro

3.48B

28.51%

Por RegiãoUSD

Nome

Receita

Proporção

United States

8.33B

68.15%

International

3.60B

29.47%

other

290.00M

2.37%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Eliquis

3.75B

30.65%

Opdivo

2.60B

21.26%

Orencia

964.00M

7.89%

Yervoy

739.00M

6.05%

Other

691.00M

5.65%

Outro

3.48B

28.51%

Distribuição de ações

Atualizado em: qui, 29 de jan

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

9.71%

BlackRock Institutional Trust Company, N.A.

4.98%

State Street Investment Management (US)

4.74%

Charles Schwab Investment Management, Inc.

3.59%

JP Morgan Asset Management

2.90%

Outro

74.08%

Investidores

Proporção

The Vanguard Group, Inc.

9.71%

BlackRock Institutional Trust Company, N.A.

4.98%

State Street Investment Management (US)

4.74%

Charles Schwab Investment Management, Inc.

3.59%

JP Morgan Asset Management

2.90%

Outro

74.08%

Tipos de investidores

Investidores

Proporção

Investment Advisor

44.78%

Investment Advisor/Hedge Fund

25.99%

Research Firm

2.97%

Pension Fund

2.58%

Hedge Fund

2.50%

Bank and Trust

2.03%

Sovereign Wealth Fund

1.74%

Insurance Company

0.19%

Family Office

0.06%

Outro

17.14%

Participação acionária institucional



Atualizado em: seg, 8 de dez

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q4

3973

1.68B

84.73%

-171.91K

2025Q3

4147

1.68B

85.10%

-5.79M

2025Q2

4212

1.69B

83.90%

+15.56M

2025Q1

4284

1.67B

82.20%

-238.41K

2024Q4

4280

1.64B

80.20%

+45.34M

2024Q3

4106

1.59B

79.76%

+6.69M

2024Q2

4097

1.58B

82.24%

-51.64M

2024Q1

4107

1.64B

80.22%

+12.13M

2023Q4

4104

1.60B

80.80%

-21.68M

2023Q3

4025

1.62B

80.17%

-24.04M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

194.95M

9.58%

+1.00M

+0.52%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

101.38M

4.98%

+2.01M

+2.02%

Sep 30, 2025

State Street Investment Management (US)

96.60M

4.74%

+1.86M

+1.96%

Sep 30, 2025

Charles Schwab Investment Management, Inc.

73.04M

3.59%

+2.24M

+3.16%

Sep 30, 2025

JP Morgan Asset Management

59.07M

2.9%

-8.34M

-12.37%

Sep 30, 2025

Geode Capital Management, L.L.C.

46.55M

2.29%

+377.61K

+0.82%

Sep 30, 2025

Norges Bank Investment Management (NBIM)

33.57M

1.65%

-1.60M

-4.55%

Jun 30, 2025

Capital International Investors

32.39M

1.59%

-33.78M

-51.05%

Sep 30, 2025

Columbia Threadneedle Investments (US)

29.79M

1.46%

+405.79K

+1.38%

Sep 30, 2025

PRIMECAP Management Company

22.09M

1.09%

-850.33K

-3.71%

Sep 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sex, 5 de dez

Nome

Proporção

VanEck Pharmaceutical ETF

9.15%

First Trust NASDAQ Pharmaceuticals ETF

7.58%

Franklin US Dividend Booster Index ETF

5.08%

WBI Power Factor High Dividend ETF

4.88%

VanEck Morningstar Wide Moat Value ETF

4.34%

iShares U.S. Pharmaceuticals ETF

4.31%

Schwab U.S. Dividend Equity ETF

3.74%

ETC 6 Meridian Hedged Equity Index Option ETF

3.68%

ETC 6 Meridian Mega Cap Equity ETF

3.58%

Brookstone Value Stock ETF

3.48%

Ver Mais

VanEck Pharmaceutical ETF

Proporção9.15%

First Trust NASDAQ Pharmaceuticals ETF

Proporção7.58%

Franklin US Dividend Booster Index ETF

Proporção5.08%

WBI Power Factor High Dividend ETF

Proporção4.88%

VanEck Morningstar Wide Moat Value ETF

Proporção4.34%

iShares U.S. Pharmaceuticals ETF

Proporção4.31%

Schwab U.S. Dividend Equity ETF

Proporção3.74%

ETC 6 Meridian Hedged Equity Index Option ETF

Proporção3.68%

ETC 6 Meridian Mega Cap Equity ETF

Proporção3.58%

Brookstone Value Stock ETF

Proporção3.48%

Dividendo



Um total de 18.64B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Dec 10, 2025

BMY.NB Interim Cash Dividend of gross USD 0.63 paid on Feb 02, 2026 going ex on Jan 02, 2026 with reinvestment option

Jan 02, 2026

Feb 02, 2026

Jan 02, 2026

Sep 17, 2025

BMY.NB Final Cash Dividend of gross USD 0.62 paid on Nov 03, 2025 going ex on Oct 03, 2025 with reinvestment option

Oct 03, 2025

Nov 03, 2025

Oct 03, 2025

Jun 17, 2025

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Aug 01, 2025 going ex on Jul 03, 2025 with reinvestment option

Jul 03, 2025

Aug 01, 2025

Jul 03, 2025

Mar 03, 2025

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on May 01, 2025 going ex on Apr 04, 2025 with reinvestment option

Apr 04, 2025

May 01, 2025

Apr 04, 2025

Dec 11, 2024

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option

Jan 03, 2025

Feb 03, 2025

Jan 03, 2025

Sep 10, 2024

BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option

Oct 04, 2024

Nov 01, 2024

Oct 04, 2024

Jun 18, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option

Jul 05, 2024

Aug 01, 2024

Jul 05, 2024

Mar 01, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option

Apr 05, 2024

May 01, 2024

Apr 04, 2024

Dec 06, 2023

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option

Jan 05, 2024

Feb 01, 2024

Jan 04, 2024

Sep 20, 2023

BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023

Oct 06, 2023

Nov 01, 2023

Oct 05, 2023

Ver Mais

Desdobramento de ações



Data

Data ex-dividendo

Tipo

Proporção

Sem dados

Data

Data ex-dividendo

Tipo

Proporção

Sem dados